[Clues to differentiate pregnancy-associated breast cancer from those diagnosed in postpartum period: A monocentric experience of pregnancy-associated cancer network (CALG)]

Bull Cancer. 2017 Jun;104(6):574-584. doi: 10.1016/j.bulcan.2017.03.012. Epub 2017 May 4.
[Article in French]

Abstract

Purpose: To compare epidemiological, histological, therapeutic characteristics and prognosis of patients with breast cancer diagnosed during pregnancy with those diagnosed in postpartum period at a national expert center, « Cancer Associé à La Grossesse » network.

Methods: Retrospective study of 108 patients with a pregnancy-associated breast cancer (PABC) between 2002 and 2016 comparing 51 patients with PABC during pregnancy and 57 patients with PABC of postpartum.

Results: Median gestational age at diagnosis was 16 weeks of gestation (WG). Median size (P=0.92), initial axillary pathology (P=0.29), histological type (P=0.33) and hormone receptor positive (P=0.93), were similar between groups. PABC during pregnancy overexpressed less frequently HER2 (12 % vs 36 %, P=0.003) and were less proliferant (Ki67≥15 %; 64 % vs 75 %, P=0.018) with less radical surgery (45 % vs 70 %, P=0.008). Sentinel lymph node biopsy was performed in 8 patients during pregnancy. Less patients of PABC during pregnancy received trastuzumab 12 % vs 37 %, P=0.003. Median delivery term was 37 WG. Median follow-up 3.2 vs 5.6 years (P=0.002) and recurrence rate for PABC during pregnancy and of postpartum were 3.2 vs 5.6 years (P=0.002) and 12 % vs 32 % (P=0.01), respectively. Our results emphasize histological, surgical and adjuvant treatment differences imposing differentiating PABC during pregnancy from those diagnosed in the postpartum period.

Keywords: Breast cancer; CSAG; Cancer du sein; Chirurgie; Grossesse; Histologie; Histology; PABC; Pregnancy; Recurrence; Récidive; Surgery.

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Axilla
  • Breast Neoplasms* / diagnosis
  • Breast Neoplasms* / metabolism
  • Breast Neoplasms* / pathology
  • Breast Neoplasms* / therapy
  • Diagnosis, Differential
  • Female
  • Gestational Age
  • Humans
  • Ki-67 Antigen / metabolism
  • Mastectomy / statistics & numerical data
  • Neoplasm Recurrence, Local
  • Postpartum Period*
  • Pregnancy
  • Pregnancy Complications, Neoplastic* / diagnosis
  • Pregnancy Complications, Neoplastic* / metabolism
  • Pregnancy Complications, Neoplastic* / pathology
  • Pregnancy Complications, Neoplastic* / therapy
  • Pregnancy Outcome
  • Prognosis
  • Receptor, ErbB-2 / metabolism
  • Retrospective Studies
  • Time Factors
  • Trastuzumab / therapeutic use

Substances

  • Antineoplastic Agents
  • Ki-67 Antigen
  • Receptor, ErbB-2
  • Trastuzumab